About Us

serenity lake
serenity sand
serenity dock
serenity butterfly

The Serenity Foundation, a 501(c)(3) not-for-profit organization, was formed and organized to address a much-needed void in the field of mental health services. Our mission is to provide assistance to the many patients turning to an entirely new and innovative class of medications to treat their mental illness with a level of efficacy never before seen. Within this category of drugs, Ketamine is the only FDA-approved medication currently being utilized and it is also the most extensively studied. Ketamine was first FDA approved as a drug for anesthesia in 1970, and it was in 2000 when Yale University first reported its surprisingly high success rate and speed at which it was able to relieve major depression. Since then, dozens of studies have duplicated those findings, showing that ketamine administered intravenously via infusion is 70-75% effective for relieving the most difficult cases of this affliction, specifically “Treatment-Resistant Depression” or TRD. Not only is Ketamine this effective, but the relief it provides can be seen as quickly as just hours or days from treatment and can last for up to months later. Studies have also shown that in addition to its quick and effective benefits, Ketamine has minimal to no side effects, hence rapidly turning around the lives of many of those suffering in an amazingly short time.

Since intravenous Ketamine has not yet been FDA-approved specifically for the use of mental illnesses, medical insurance does not cover the cost. Thus, the many clinics now offering this valuable service must ask patients to pay cash for the treatment. As a result, the out-of-pocket costs can be both prohibitive and unsustainable for many. The Serenity Foundation and its Board saw Ketamine infusion treatment for mental illness as a much-needed service that should not discriminate based on a patient’s financial capabilities. These psychiatric services are crucial to the health and well-being of our society. According to the World Health Organization (“WHO”), major depression is the leading cause of disability and lost productivity in the workplace in the world.

At least 90% of all donated funds will go directly to sponsored Ketamine treatment costs. In addition, with the current COVID-19 pandemic and many job losses, financial stressors, and future uncertainties, the rate of depression, anxiety, and PTSD has been said to have doubled or tripled. Now more than ever, The Serenity Foundation is needed to finally help provide a novel and highly effective treatment to those who do not have the means, by delivering financial assistance to qualifying patients. The Serenity Foundation will seek donor funds from not only philanthropic donors and mental health advocates, but also from organizations in the mental health and wellness space in order to achieve our mission.

The Serenity Foundation was formed and organized to address a much-needed void in the field of mental health services. Our mission is to provide assistance to the many patients turning to an entirely new and innovative class of medications to treat their mental illness with a level of efficacy never before seen. Within this category of drugs, Ketamine is the only FDA-approved medication currently being utilized and it is also the most extensively studied. Ketamine was first FDA approved as a drug for anesthesia in 1970, and it was in 2000 when Yale University first reported its surprisingly high success rate and speed at which it was able to relieve major depression. Since then, dozens of studies have duplicated those findings, showing that ketamine administered intravenously via infusion is 70-75% effective for relieving the most difficult cases of this affliction, specifically “Treatment Resistant Depression” or TRD. Not only is Ketamine this effective, but the relief it provides can be seen as quickly as just hours or days from treatment and can last for up to months later. Studies have also shown that in addition to its quick and effective benefits, Ketamine has minimal to no side effects, hence rapidly turning around the lives of many of those suffering in an amazingly short time.

serenity lake

Since intravenous Ketamine has not yet been FDA-approved specifically for the use of mental illnesses, medical insurance does not cover the cost. Thus, the many clinics now offering this valuable service must ask patients to pay cash for the treatment. As a result, the out-of-pocket costs can be both prohibitive and unsustainable for many. The Serenity Foundation and its Board saw Ketamine infusion treatment for mental illness as a much-needed service that should not discriminate based on a patient’s financial capabilities. These psychiatric services are crucial to the health and well-being of our society. According to the World Health Organization (“WHO”), major depression is the leading cause of disability and lost productivity in the workplace in the world.

serenity sand

At least 90% of all donated funds will go directly to sponsored Ketamine treatment costs. In addition, with the current COVID-19 pandemic and many job losses, financial stressors, and future uncertainties, the rate of depression, anxiety, and PTSD has been said to have doubled or tripled. Now more than ever, The Serenity Foundation is needed to finally help provide a novel and highly effective treatment to those who do not have the means, by delivering financial assistance to qualifying patients. The Serenity Foundation will seek donor funds from not only philanthropic donors and mental health advocates, but also from organizations in the mental health and wellness space in order to achieve our mission.

serenity dock

Partners

IV Solution Logo

NAMI Logo
Does your organization want to become a Serenity Partner? Contact us at info@serenityfoundationusa.org.